Novel molecular formats - Fc-fusion proteins, bispecific antibodies, and Fab fragments - are driving therapeutic ...
The company has a flexible approach that makes use of its antibody platform downstream process where appropriate, and augments its development process with high-throughput (HT) approaches to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results